ITCI - Intra-Cellular Therapies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue-245.837330.70291.364
Cost of Revenue132,166.91379,419.00993,831.5387,718.074
Gross Profit-132,166.913-79,173.172-93,500.828-87,626.71
Operating Expenses
Research Development----
Selling General and Administrative30,099.85523,666.95724,758.06318,187.286
Non Recurring----
Others----
Total Operating Expenses162,266.768103,085.966118,589.593105,905.36
Operating Income or Loss-162,266.768-102,840.129-118,258.891-105,813.996
Income from Continuing Operations
Total Other Income/Expenses Net7,140.9574,005.8642,898.2961,022.455
Earnings Before Interest and Taxes-162,266.768-102,840.129-118,258.891-105,813.996
Interest Expense---36.781-36.781
Income Before Tax-155,125.811-98,834.265-115,360.595-104,791.541
Income Tax Expense1.6-1,060.8511,065.6731.6
Minority Interest----
Net Income From Continuing Ops-155,127.411-97,773.414-116,426.268-104,793.141
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-155,127.411-97,773.414-116,426.268-104,793.141
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-155,127.411-97,773.414-116,426.268-104,793.141